Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new drug combo outsmart Hard-to-Treat myeloma?

NCT ID NCT07728188

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This phase 3 trial is testing whether an experimental drug called etentamig, combined with pomalidomide, can control multiple myeloma that has come back or stopped responding to treatment. About 520 adults who have already tried 1 to 3 prior therapies will be randomly assigned to receive either the new combination or one of several standard treatments. The study will compare how well each approach shrinks tumors and delays disease progression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an experimental drug called etentamig combined with pomalidomide
What this could lead to
If successful, this combination could offer a new treatment option for people with multiple myeloma that has returned or not responded to prior therapy.
What could go wrong
This is an early-phase trial, so the combination may not prove more effective or safer than existing treatments. Side effects are possible and will be closely monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 520 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Feb 2033

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of relapsed or refractory (RR) multiple myeloma (MM). * Prior treatment with at least one and no more than three prior lines of therapy, including lenalidomide. * Adequate organ function and performance status Exclusion Criteria: * Prior B-cell maturation antigen (BCMA) directed T-cell engager therapy (bispecific or trispecific) * Known central nervous system involvement of MM * Known history of other active malignancies within the past 3 years (with specific exceptions) * Clinically significant conditions (renal, neurologic, psychiatric, endocrine, metabolic, immunologic, cardiovascular, pulmonary, or hepatic disease within the last 6 months)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Relapsed or refractory multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm plasma cell myeloma Recurrence refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Relapsed or refractory multiple myeloma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    66 sites in 13 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • 2CA-Braga, Hospital de Braga /ID# 283828

    Braga, 4710-243, Portugal

  • Beth Israel Deaconess Medical Center /ID# 285204

    Boston, Massachusetts, 02215, United States

  • British Columbia Cancer Agency Vancouver Centre /ID# 282147

    Victoria, British Columbia, V8R 6V5, Canada

  • CHRU Tours - Hopital Bretonneau /ID# 281925

    Tours, Indre-et-Loire, 37044, France

  • Cancer And Hematology Centers Of Western Michigan - Grand Rapids /ID# 282591

    Grand Rapids, Michigan, 49503, United States

  • Centre Hospitalier Regional Universitaire de Nancy - Hopitaux de Brabois /ID# 284303

    Vandœuvre-lès-Nancy, Meurthe-et-Moselle, 54511, France

  • Centre Hospitalier Universitaire de Nantes - L' Hopital l'hotel-Dieu /ID# 282025

    Nantes, Pays de la Loire Region, 44000, France

  • Centre Hospitalier d'Avignon /ID# 283509

    Avignon, Provence-Alpes-Côte d'Azur Region, 84000, France

  • Centro Hospitalar De Lisboa Ocidental - Hospital De Sao Francisco Xavier /ID# 283500

    Lisbon, Lisbon District, 1449-005, Portugal

  • Chu de Nice-Hopital Larchet Ii /Id# 283541

    Nice, Alpes-Maritimes, 06202, France

  • Cleveland Clinic Florida /ID# 283692

    Weston, Florida, 33331, United States

  • Clinica Universidad de Navarra - Pamplona /ID# 283290

    Pamplona, Navarre, 31008, Spain

  • Columbia University Medical Center /ID# 283510

    New York, New York, 10032, United States

  • Duke University Medical Center /ID# 283475

    Durham, North Carolina, 27710, United States

  • Epworth Hospital - Richmond /ID# 281877

    Richmond, Victoria, 3121, Australia

  • Erasmus Medisch Centrum /ID# 283408

    Rotterdam, South Holland, 3015 CE, Netherlands

  • Fiona Stanley Hospital /ID# 281879

    Murdoch, Western Australia, 6150, Australia

  • Haukeland University Hospital /ID# 283524

    Bergen, Sogn Og Fjordane, 5021, Norway

  • Hospital General Universitario Gregorio Maranon /ID# 283342

    Madrid, 28007, Spain

  • Hospital Universitario Marques de Valdecilla /ID# 283344

    Santander, Cantabria, 39008, Spain

  • Huntsman Cancer Institute /ID# 283512

    Salt Lake City, Utah, 84112, United States

  • Icon Cancer Care - South Brisbane /ID# 282965

    South Brisbane, Queensland, 4101, Australia

  • Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST - IRCCS /ID# 281398

    Meldola, Forlì-Cesena, 47014, Italy

  • Kaohsiung Chang Gung Memorial Hospital /ID# 282970

    Kaohsiung City, 833, Taiwan

  • Krh Klinikum Siloah-Oststadt-Heidehaus /ID# 283729

    Hanover, Lower Saxony, 30459, Germany

  • Leids Universitair Medisch Centrum /ID# 283142

    Leiden, South Holland, 2333 ZA, Netherlands

  • London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 282149

    London, Ontario, N6A 5W9, Canada

  • MD Anderson Houston /ID# 282622

    Houston, Texas, 77030-4000, United States

  • MedStar Georgetown University Hospital /ID# 283734

    Washington D.C., District of Columbia, 20007, United States

  • NHS Lanarkshire /ID# 282021

    Airdrie, North Lanarkshire, ML6 0JS, United Kingdom

  • Northwest Georgia Oncology Centers /ID# 284769

    Marietta, Georgia, 30060, United States

  • Nottingham City Hospital /ID# 282748

    Nottingham, Nottinghamshire, NG5 1PB, United Kingdom

  • Novant Health Forsyth Medical Center /ID# 283485

    Winston-Salem, North Carolina, 27103, United States

  • Oregon Health and Science University /ID# 282023

    Portland, Oregon, 97239, United States

  • Peter MacCallum Cancer Centre. /ID# 282692

    Melbourne, Victoria, 3000, Australia

  • Pindara Private Hospital /ID# 283010

    Benowa, Queensland, 4217, Australia

  • Queen Alexandra Hospital /ID# 281839

    Portsmouth, Hampshire, PO6 3LY, United Kingdom

  • Rush University Medical Center /ID# 283095

    Chicago, Illinois, 60612, United States

  • SCRI Oncology Partners /ID# 281380

    Nashville, Tennessee, 37203, United States

  • Sir Charles Gairdner Hospital /ID# 281881

    Nedlands, Western Australia, 6009, Australia

  • St Bartholomews Hospital - Barts Health /ID# 283714

    London, Greater London, EC1A 7BE, United Kingdom

  • Staedtisches Klinikum Karlsruhe /ID# 283569

    Karlsruhe, Baden-Wurttemberg, 76133, Germany

  • The Mount Sinai Hospital /ID# 283535

    New York, New York, 10029, United States

  • Toi Clinical Research - Whittier /ID# 284462

    Cerritos, California, 90703, United States

  • Unidade Local de Saude Sao Joao /ID# 283530

    Porto, 4200-319, Portugal

  • Unidade Local de Saude de Gaia/Espinho /ID# 283492

    Vila Nova de Gaia, Porto District, 4434-502, Portugal

  • Universitaetsklinikum Bonn /ID# 283881

    Bonn, North Rhine-Westphalia, 53127, Germany

  • Universitaetsklinikum Freiburg /ID# 282874

    Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany

  • Universitaetsklinikum Koeln /ID# 283930

    Cologne, North Rhine-Westphalia, 50937, Germany

  • Universitaetsklinikum Tuebingen /ID# 282873

    Tübingen, Baden-Wurttemberg, 72076, Germany

  • Universitaetsklinikum Ulm /ID# 283884

    Ulm, Baden-Wurttemberg, 89081, Germany

  • Universitaetsklinikum Wuerzburg /ID# 283572

    Würzburg, Bavaria, 97080, Germany

  • Universite de Montreal - Hopital Maisonneuve-Rosemont /ID# 281705

    Montreal, Quebec, H1T 2M4, Canada

  • University Hospitals Cleveland Medical Center /ID# 283527

    Cleveland, Ohio, 44106, United States

  • University Hospitals Plymouth NHS Trust /ID# 283108

    Plymouth, Devon, PL6 8DH, United Kingdom

  • University Of Colorado - Anschutz Medical Campus /ID# 283478

    Aurora, Colorado, 80045, United States

  • University of Arizona Cancer Center /ID# 285339

    Tucson, Arizona, 85704, United States

  • University of California Los Angeles /ID# 282444

    Los Angeles, California, 90095-3075, United States

  • University of North Carolina Lineberger Comprehensive Cancer Center /ID# 281454

    Chapel Hill, North Carolina, 27599, United States

  • University of Rochester Medical Center /ID# 283480

    Rochester, New York, 14642, United States

  • University of Wisconsin Hospitals and Clinics /ID# 282516

    Madison, Wisconsin, 53792, United States

  • VCU Massey Cancer Center: Dalton Oncology Clinic /ID# 283606

    Richmond, Virginia, 23298, United States

  • Vas Varmegyei Markusovszky Egyetemi Oktatokorhaz /ID# 283136

    Szombathely, Vas County, 9700, Hungary

  • Weill Cornell Medicine - Cornell University /ID# 283712

    New York, New York, 10065, United States

  • Western General Hospital - NHS Lothian /ID# 281838

    Edinburgh, Edinburgh, City of, EH4 2XU, United Kingdom

  • Wollongong Hospital. /ID# 282694

    Wollongong, New South Wales, 2500, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.